GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split OTC Markets:GOVX


ATLANTA, GA, Sept. 24, 2020 (GLOBE NEWSWIRE) — via NewMediaWireGeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the pricing of its underwritten public offering of 2,560,000 units at a price to the public of $5.00 per unit. Each unit issued in the offering consists of one share of common stock (or pre-funded warrant to purchase common stock in lieu thereof) and one warrant to purchase one share of common stock at an exercise price of $5.00. The common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants are immediately separable and will be issued separately. The common stock and warrants are expected to begin trading on the Nasdaq Capital Market, on September 25, 2020, under the symbols “GOVX” and “GOVXW,” respectively. GeoVax expects to receive gross proceeds of $12.8 million, before deducting…

Click here for the full story.

FTSE Russell Says China to Be Included in Global Bond Index By Bloomberg

Previous article

G7 finance ministers seen backing extension of debt freeze for poorest nations

Next article

You may also like

Leave a Reply

Notify of

More in Earnings